BNGO - CIK 0001411690
The table below shows Bionano Genomics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$16.34M | -$68.92M | -$125.18M | -$124.82M | -$71.93M | -$38.31M |
| Capital expenditure | - | - | - | - | - | $0.00 |
| Investing cash flow | -$12.75M | $73.84M | $24.16M | $82.77M | -$278.06M | -$2.45M |
| Dividends paid | - | - | - | - | - |
Bionano Genomics, Inc. reported operating cash flow of -$16.34M for fiscal year 2025. That is up 76.3% from -$68.92M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$20.82M (FY 2017) to -$16.34M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $24.04M | -$13.69M | $113.81M | $23.01M | $336.11M | $61.90M |